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ABSTRACT
Background. Psychotropic medications, in particular second-generation antipsy-
chotics (SGAs) and benzodiazepines, have been associated with harm in elderly
populations. Health agencies around the world have issued warnings about the risks
ofprescribingsuchmedicationstofrailindividualsaVectedbydementiaandcurrent
guidelinesrecommendtheiruseonlyincaseswherethebeneﬁtsclearlyoutweighthe
risks.Thisstudydocumentstheuseofpsychotropicmedicationsintheentireelderly
populationofaCanadianprovinceinthecontextofcurrentclinicalguidelinesforthe
treatmentofbehaviouraldisturbances.
Methods. Prevalent and incident utilization of antipsychotics, benzodiazepines and
related medications (zopiclone and zaleplon) were determined in the population of
Manitobans over age 65 in the time period 1997/98 to 2008/09 ﬁscal years. Com-
parisons between patients living in the community and those living in personal care
(nursing) homes (PCH) were conducted. Inﬂuence of sociodemographic character-
istics on prescribing was assessed by generalized estimating equations. Non-optimal
use was deﬁned as the prescribing of high dose of antipsychotic medications and
the use of combination therapy of a benzodiazepine (or zopiclone/zaleplon) with
an antipsychotic. A decrease in intensity of use over time and lower proportions of
patients treated with antipsychotics at high dose or in combination with benzodi-
azepines (or zopiclone/zaleplon) was considered a trend toward better prescribing.
Multiple regression analysis determined predictors of non-optimal use in the elderly
population.
Results. A 20-fold greater prevalent utilization of SGAs was observed in PCH-
dwelling elderly persons compared to those living in the community. In 2008/09,
27% of PCH-dwelling individuals received a prescription for an SGA. Patient char-
acteristics, such as younger age, male gender, diagnoses of dementia (or use of an
acetylcholinesterase inhibitor) or psychosis in the year prior the prescription, were
predictors of non-optimal prescribing (e.g., high dose antipsychotics). During the
period 2002/3 and 2007/8, amongst new users of SGAs, 10.2% received high doses.
Thosereceivinghighdoseantipsychoticsdidnotshowhighlevelsofpolypharmacy.
Conclusions. Despite encouraging trends, the use of psychotropic medications re-
mainshighinelderlyindividuals,especiallyinresidentsofnursinghomes.Clinicians
caringforsuchpatientsneedtocarefullyassessrisksandbeneﬁts.
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INTRODUCTION
Antipsychotic medications have been prescribed to elderly persons mainly for the
treatment of behavioural disturbances of dementia (Chan, Lam & Chen, 2011; Leslie
& Rosenheck, 2012; Lee et al., 2004; Tariot, 2004). The safety and eVectiveness of both
ﬁrst-generation (FGAs; e.g., haloperidol and phenothiazines) and second-generation
antipsychotic agents (SGAs; e.g., risperidone, olanzapine, quetiapine) have been
questioned and severe adverse events, including death, have been reported in elderly
patients treated with antipsychotics in both RCTs and observational studies (Ray et al.,
2001; Percudani et al., 2005; Wang, Schneeweiss & Avorn, 2005; Schneeweiss et al., 2007;
Triﬁroetal.,2007;Mehtaetal.,2010;Sacchetti,Turrina&Valsecchi,2010;Mittaletal.,2011;
Vasilyeva et al., 2013). Because of the strong evidence of harm caused by these agents to
elderlypatientsaVectedbydementia,HealthCanadaandotherhealthagenciesworldwide
issued several warnings between 2002 and 2005 (Health Canada, 2002; Health Canada,
2004; Health Canada, 2005; The Food and Drug Administration, 2008; European Medicines
Agency(EMEA),2009).Benzodiazepines(BZDs)andotherpsychotropicmedicationshave
also been associated with harm (e.g., increased risk of falls) in older adults (Eigenbrodt
et al., 2000; Ayer et al., 2007; Barlett, Abrahamowicz & Grad, 2009; Hill & Wee, 2012),
and evidence-based practice guidelines advise clinicians to consider all factors before
prescribing potent medications to frail individuals (APA Practice Guidelines, 2007; Peisah,
Chan & McKay, 2011; Jeste, Blazer & Casey, 2008; Gauthier, Patterson & Chertkow, 2012).
Theobjectivesofthisstudywere:
1. to evaluate the use of psychotropic medications (i.e., antipsychotics and benzodi-
azepines) in the elderly population of a Canadian province in light of health agency
warningsandoptimalprescribingguidelines;
2. to determine predictors of non-optimal use of psychotropic medication in elderly
persons.
METHODS
This retrospective population-based study received ethics approval from the Research
Ethics Board of the University of Manitoba. The study was conducted in full compliance
withthePersonalHealthInformationActofManitoba(PersonalHealthInformationActof
Manitoba,2013)andapprovedbytheprovincialHealthInformationPrivacyCommittee.
Data for the study were obtained from the administrative health care databases of
the Manitoba Population Health Research Data Repository, housed at the Manitoba
Centre for Health Policy. The databases include de-identiﬁed information on the entire
population of the province and the use of a consistent set of quasi-identiﬁers permits the
building of health histories of non-identiﬁable individuals across ﬁles and time. Nearly all
contacts with the universal provincial health care system, including physicians, hospitals,
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recorded.Allregisteredindividualspossessa9-digitpersonalhealthidentiﬁcationnumber
(PHIN), which is encrypted to protect privacy. The following databases were accessed:
(1) population registry, (2) hospital abstracts, (3) medical services, (4) Drug Product
Information Network (DPIN) prescription records, (5) PCH records, (6) vital statistics
and(7)prescribercharacteristics.
Records of physician reimbursement for medical care (ambulatory care visits and
hospitalizations) are submitted under a fee-for-service arrangement and contain
information on patient diagnosis based on the International Classiﬁcation of Diseases,
Clinical Modiﬁcation (ICD-9-CM and ICD-10-CM codes) (International Classiﬁcation
of Diseases, 2013). Records of dispensed prescriptions (DPIN) available through retail
pharmaciescontaindataonthedateofdispensing,drugname,strength,dosageform,and
quantity, and the 8-digit drug identiﬁcation number (DIN). Diagnoses can be retrieved
from the hospital abstracts and medical services databases and linked with the population
registry and vital statistics for demographic characteristics of patients and dates of death.
Prescribercharacteristicsfocusontheprescriberwhowrotetheincidentprescription.
Region of residence (urban vs. rural) was determined by the postal codes registered
with Manitoba Health. The distribution of urban (major cities of the province, Winnipeg
and Brandon) versus rural (small communities across the province) population is
approximately72%versus28%(StatisticsCanada,2013).
Socioeconomicstatus(SES)wasdeterminedonthebasisofthemedianneighbourhood
incomequintilesfromStatisticsCanada(StatisticsCanada,2013):lowincomeincludedthe
lowestandsecondlowestquintiles,highincomeincludedthethreehighestquintiles.
We included all Manitoba residents aged 65 years and older over an 11-year period.
Separate analyses were conducted to evaluate prevalent and incident utilization of
antipsychotics, BZDs, zopiclone (ZOP) and zaleplon (ZAL) in elderly persons living
in the community or in PCH. SGAs available in Manitoba at the time of the study
were clozapine, risperidone, olanzapine and quetiapine. Clozapine utilization in the
elderly population of Manitoba has been negligible and restricted to patients with
treatment-resistant-schizophrenia; therefore, it was not included in the analyses. Please
refer to Appendix 1 for a complete list of BZDs and related medications. It is important
to note that ZAL was discontinued in Canada by the manufacturer in September 2007
(Health Canada, 2013). Incident users were deﬁned as individuals who were registered
with the provincial health care system and had not received a prescription for the
medication of interest in the year prior to the ﬁrst prescription. Prevalence of use was
also evaluated as deﬁned-daily-dose (DDD) per 1,000 patients per day, which represented
a measurement of intensity of use. The DDD is the average daily dose for a medication
dispensed for the main indication in usual practice and is calculated according to the
guidelines of the WHO Collaborating Centre for Drug Statistics Methodology (World
HealthOrganization,2013).Thetimeframeofthestudywasbetween1997/98and2008/09
by ﬁscal year (01 April to 31 March for each year). Generalized estimating equation
(GEE) modeling (VittinghoV, Glidden & Shiboski, 2012) was used to assess the inﬂuence
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medicationsovertime.
Non-optimal use deﬁnitions included incident prescription of high dose SGAs
(i.e., 1:5 mg=day for risperidone, 10 mg=day olanzapine, 200 mg=day quetiapine)
(World Health Organization, 2013) within the ﬁrst year of use, use of SGAs in PCH
residents with a concomitant prescription of an acetylcholinesterase inhibitor (AChEI)
(donepezil, galantamine, rivastigmine) within the same year, or a concomitant pre-
scription of an antipsychotic and a BZD, ZOP or ZAP within the same quarter. Other
medications such as memantine that can be prescribed to individuals with dementia were
notincludedintheanalysisbecauseofnegligibleutilizationintheprovinceand/orbecause
ofoverlappingprescribingwithanAChEI.
Logistic regression modeling was used to identify predictors of non-optimal use. Vari-
ablesincludedinthemodelwere:prescribers’characteristics(e.g.,age,sex,speciality,type
of practice, hospital aYliation), patient sociodemographic characteristics and measures
of health services utilization in the year prior to the ﬁrst antipsychotic prescription
(i.e., number of hospitalizations and ambulatory visits, number of medications, use of
AChEIs, psychosis diagnosis identiﬁed by ICD9-CM 295-299, ICD–10–CM: F2, F3, F84,
R410, co-morbidities as assessed by the number of major Aggregated Diagnostic Groups
(ADGs), as deﬁned in the Johns Hopkins ACG (Adjusted Clinical Group) Case-Mix
System(softwareversion9)(Reidetal.,2013;TheManitobaCentreforHealthPolicy,2013).
Since time eVects are important in changing prescribing patterns, optimal use evaluations
were conducted in incident users between 2002/03 and 2008/09, as this was the interval
thatwouldbestassessthepossibleeVectofthewarnings.
AnalyseswereperformedusingSAS statisticalsoftware,version9.2(SASInstituteInc.,
Cary,NorthCarolina,USA).
RESULTS
Utilization: community-dwelling population
A total of 143,491 community-dwelling adults over 65 years of age represented the
populationdenominatorin1997/98,and153,189in2008/09.
Prevalent utilization of SGAs increased from 0.6 to 13.5 users per 1,000 community-
dwelling older adults while the use of FGAs declined from 12.8 to 5.9 users per 1,000.
Risperidone was the most prescribed agent with an increase in prevalence from 0.6 to 6.5
per1,000(olanzapineuseincreasedfrom0.05to3.7per1,000andquetiapineuseincreased
from 0.07 to 3.9 per 1,000) during the study period. The use of BZDs was greater than the
useofantipsychoticsinthispopulationbutlittlechangeinprevalencewasobserved(108.6
to109.1usersper1,000);however,ZOPandZALuseincreasedfrom13.6to53.0usersper
1,000 during the same time interval. Prevalence of users receiving a combination of SGAs
andBZD(orZOP,ZAL)increasedfrom0.2to5.61per1,000.
DoseintensityofSGAsincreasedfrom0.2DDDper1,000in1997/98toapeakof6.5per
1,000in2004/05andsubsequentlydecreasedto4.9bytheendofthestudyperiod,2008/09.
Alessi-Severini et al. (2013), PeerJ, DOI 10.7717/peerj.168 4/13Table1 Incidentuseincommunity-dwellingolderadults(65C).
Medications SGAs FGAs BZDs/ZOP,ZAL BZDs/ZOP,ZALCSGA
Users/1,000 Year 1998 0.21 1.88 13.14 0.06
Users/1,000 Year 2009 1.63 1.03 13.66 0.15
Change in rate per quarter 1.02* 0.98* 1.00 NS 1.01*
Age eVect 65–84 vs. 85C 0.44* 0.85* 1.08* 0.60*
SES eVect low vs. high 1.10* 1.14* 1.00 NS 1.09 NS
Region eVect rural vs. urban 0.88* 1.51* 1.01 NS 1.02 NS
Sex eVect male vs. female 0.91* 0.86* 0.73* 1.17*
Notes.
Results for change in quarterly rate, age, SES, region and sex eVects are presented as relative rates (adjusted for age, SES,
region, sex and time).
SGAs, second generation antipsychotics; FGAs, ﬁrst generation antipsychotics; BZDs/ZOP, ZAL, benzodiazepines,
zopiclone, zaleplon; NS, not signiﬁcant; SES, socioeconomic status.
* Indicates a statistically signiﬁcant eVect .p < 0:05/.
For BZDs the change in DDD was small (from 65.2 to 68.6 per 1,000) while for ZOP and
ZAL,itincreasedfrom9.5to49.6per1,000.
Incidence rates per quarter increased signiﬁcantly for SGA users and for users of
combination therapy over the time period of the study. Age and gender had a signiﬁcant
eVectwithgreaterincidentutilizationinthe85andovergroupcomparedtothe65–84year
of age group for all medications and in females compared to males for the SGAs. Higher
incidentuse inmales wasobservedfor thecombination ofBZDs(or ZOP,ZAL) andSGAs
(Table1).
Utilization: PCH-dwelling population
A total of 8,516 PCH-dwelling older adults represented the denominator for this
populationin1997/98and8,818in2008/09.
PrevalentutilizationofSGAsincreasedfrom15.0to268.5usersper1,000PCH-dwelling
olderadultswhiletheuseofFGAsdeclinedfrom169.3to47.7usersper1,000.Risperidone
was again the most commonly prescribed agent with an increase in prevalence from 15.0
to 167.0 per 1,000 (quetiapine use increased from 0.9 to 67.6 per 1,000 and olanzapine
use increased from 0.8 to 49.1 per 1,000) during the study period. While the use of
BZDs declined slightly from 170.7 to 161.3 per 1,000, the use of ZOP and ZAL increased
dramatically from 15.0 to 102.6 users per 1,000 during the same time. Prevalence of users
receiving a combination of SGAs and BZD, ZOP or ZAL increased from 4.8 to 90.8 per
1,000.
Dose intensity of SGAs increased from 5.5 DDDs per 1,000 in 1997/98 to a peak of 85.5
per 1,000 in 2003/04 and subsequently declined to 70.7 by the end of the study period,
2008/09. For BZDs the increase in DDD was small from 82.1 to 84.9 per 1,000 between
1997/98 and 2003 with a decline to 67.0 by the end of the study period. For ZOP or ZAL,
therewasasigniﬁcantincreasefrom9.5to49.6per1,000overtheentirestudyperiod.
Incidence rates per quarter increased signiﬁcantly for SGAs users and for users of
combination therapy over the time period of the study. Refer to Table 2 for details of
theage,residence,andsexeVectsonincidentuseinthispopulation.
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Medications SGAs FGAs BZDs/ZOP,ZAL BZDs/ZOP,ZALCSGA
Users/1,000 Year 1998 3.76 19.61 26.66 0.70
Users/1,000 Year 2009 21.09 8.62 22.91 4.45
Change in rate per quarter 1.01* 0.98* 1.00 NS 1.01*
Age eVect 65–84 vs. 85C 1.21* 1.36* 1.13* 1.40*
Region eVect rural vs. urban 0.78* 0.85* 0.79* 0.74*
Sex eVect male vs. female 1.22* 1.38* 1.09* 1.48*
Notes.
Results for change in quarterly rate, age, region and sex eVects are presented as relative rates (adjusted for age, region,
sex and time). Individuals residing in PCH do not have values for SES.
SGAs, second generation antipsychotics; FGAs, ﬁrst generation antipsychotics; BZDs/ZOP, ZAL, benzodiazepines,
zopiclone, zaleplon; NS, not signiﬁcant; SES, socioeconomic status.
* Indicates a statistically signiﬁcant eVect .p < 0:05/.
Table3 FactorspredictiveofhighdoseSGAswithintheﬁrstyearofuse.
Variable OR 95%CI P
Age, years 0.98 0.97–0.99 <0.0001
Sex (male vs. female) 1.18 1.04–1.33 0.0095
Number of other medications 0.97 0.96–0.98 <0.0001
AChEI prescribed in the year prior to Rx 1.28 1.08–1.51 0.0041
Diagnosis for psychosis in the year prior to Rx 1.52 1.34–1.73 <0.0001
Notes.
ACHEI, acetylcholinesterase inhibitor (donepezil, galantamine, rivastigmine); OR, odds ratio; Rx, prescription.
Optimal use
There were 12,878 total incident users (community and PCH-dwelling) of antipsychotic
medications (FGAs and SGAs) between 2002/03 and 2007/08. Of these, 1,319 (10.2%)
wentontouseahighdoseofaSGAwithintheﬁrstyearoftherapy.
The rate of older adults who received a high dose SGA within the ﬁrst year of being
prescribedanSGAincreasedfrom0.4to0.82per1,000personsby2000andthendeclined
to 0.36 per 1,000 in 2008 (Fig. 1). Among incident users of antipsychotic medications, the
utilizationofhighdoseSGAsdeclinedfrom112to94per1,000from2002to2008.
The proportion of PCH residents who were concomitantly prescribed an SGA and an
AChEIinthesameyearincreasedovertimefrom0.2to17.8%in2004andslightlydeclined
to16.9%bytheendofthestudy(Fig.2).
Patients were more likely to receive a high dose SGA if they were male, had received
a prescription for an AChEI or had a diagnosis of psychosis within the year prior to the
ﬁrst prescription (Table 3). Very old patients and those treated with a greater number of
diVerent medications were less likely to receive a high dose SGA. Prescriber characteristics
anduseofotherhealthcareserviceswerenotsigniﬁcantlydiVerent.
Alessi-Severini et al. (2013), PeerJ, DOI 10.7717/peerj.168 6/13Figure 1 Crude incidence rates of high dose SGA use. High doses were deﬁned as: 1:5 mg=day for
risperidone, 10 mg=day olanzapine, 200 mg=day quetiapine. The arrows indicate the times of the
warnings issued by Health Canada.
DISCUSSION
We observed a signiﬁcant increase in antipsychotic utilization in this elderly Canadian
population. This is consistent with other reports from Canada (Valiyeva et al., 2008;
Alessi-Severini et al., 2008; The Canadian Institute for Health Information, 2009), Europe
(Martinez, Jones & Rietbrock, 2013; Schulze et al., 2013) and the US (Kales et al., 2011).
GreaterutilizationofSGAswasobservedinurbanelderlypersonsandinparticularamong
PCH residents. In fact, a 20-fold greater utilization was observed in PCH-dwelling elderly
when compared to those living in the community. By the end of the study period, more
than 25% of PCH-dwelling older individuals had received an SGA. Prevalence of BZD
use remained above 10% in both community- and PCH-dwelling elderly over the time
period of the study, while ZOP and ZAL utilization increased signiﬁcantly. We observed
greateruseofFGAsamongstruralcommunitydwellingelderly,butnotamongruralPCH
dwellers. This could possibly be explained by oV-label use of FGAs, such as treatment of
chemotherapy-related nausea. Another reason could be a slower adoption of the newer
agentsbymoreisolatedpracticesites.
It seems that prescribers in the province of Manitoba have somewhat responded to
warnings about potential harm to the elderly populations from treatment with SGAs
(Health Canada, 2005; Health Canada, 2002; Health Canada, 2004; The Food and Drug
Administration, 2008; European Medicines Agency (EMEA), 2009): the dose intensity
declined in community-dwelling and reached a plateau in PCH-dwelling residents after
the warnings were issued and only a minority (approximately 10%) received potentially
Alessi-Severini et al. (2013), PeerJ, DOI 10.7717/peerj.168 7/13Figure 2 Proportion of PCH residents receiving an SGA in combination with AChEIs. PCH, personal
carehome(nursinghome);SGA,second-generationantipsychotic;AChEI,acetylcholinesteraseinhibitor.
inappropriate high doses of antipsychotic medications. Even though a decline would have
been desirable, the sign of a lower incidence of new prescriptions can be interpreted as
a positive trend. As well, the proportion of new users of SGAs who were also prescribed
AChEIsreachedaplateauafterthewarningsofseriousadverseeventsinelderlyindividuals
with dementias were released; however, no causality can be inferred as the study was not
designedtoassesstheeVectsofanintervention,buttoobservechanginginprescribingpat-
terns. While some ﬁndings might be diYcult to interpret, the higher use of SGAs in PCH
reﬂects a reality of a sicker population more susceptible to psychosis and agitation sec-
ondarytodementia;moreover,theobservationthatmalesseemmorelikelytoreceivehigh
dose SGAs can be interpreted with a higher incidence of symptoms of aggression in male
dementia patients. On the other hand, the observed lower occurrence of high dose SGAs
inveryoldpatientsand/oronmultipletherapiesappearstobeconsistentwithappropriate
prescribingtofrailindividuals.Clinicalstudiesareneededtoconﬁrmtheseassumptions.
Limitations to measures of optimal use of prescription medications using administra-
tive databases include the lack of clinical information regarding severity of symptoms, use
of over-the-counter medications, alcohol use and parameters of quality of life. Because
of the lack of clinical outcome information, this study does not allow for assessment
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medications such as high dose SGAs may in fact be appropriate therapy for a particular
patientataparticulartimewithappropriateclosemonitoringandfollowup.
It is important to note also that in Manitoba, up to 27% of PCHs do not have
medications ﬁlled through community pharmacies (Doupe, Brownell & Kozyrskyj, 2006)
and are, therefore, not captured in the DPIN system; however, the proportion of elderly
patients who reside in PCHs is limited (less than 6%) and no evidence of signiﬁcant
diVerences in patients’ characteristics has been shown among all PCHs in the province
(Doupe, Brownell & Kozyrskyj, 2006). As a consequence, the missing data should not
introduce a selection bias nor aVect the validity of the results. A strength of these analyses
is, in fact, in the comprehensive nature of the administrative health claims data, which
includenearlyallManitobans:ourresultsarenotaVectedbysamplingerrorsorrecallbias.
Furthermore, all studied psychotropic medications are available as unrestricted beneﬁts
on the provincial formulary, which allowed access to medications to be unaVected by SES
and reimbursementconditions. Forthe PCH-dwellingolder adults,medications arelikely
administeredbyPCHstaV,somedicationadherenceisassured.
Inconclusion,despiteencouragingtrends,theuseofpsychotropicmedicationsremains
high in elderly individuals, especially in residents of PCH. Clinicians caring for such
patients need to carefully assess risks and beneﬁts. Current recommendations call for
the use of pharmacotherapy only when psychotic symptoms and agitation are persistent,
recurrent or cause clinically signiﬁcant functional disruption; the lowest possible eVective
doseofantipsychoticsshouldbeusedwhennecessaryandaregularmonitoringofeYcacy,
safetyandtolerabilityshouldbeconducted(APAPracticeGuidelines,2007;Peisah,Chan&
McKay,2011;Jeste,Blazer&Casey,2008;Gauthier,Patterson&Chertkow,2012).
ACKNOWLEDGEMENTS
The authors acknowledge the Manitoba Centre for Health Policy, University of Manitoba,
foruseofdatacontainedinthePopulationHealthResearchDataRepositoryunderproject
2008/2009–24,andderivedformdataprovidedbyManitobaHealth.Thisworkwaspartof
arequestofManitobaHealth;however,theresultsandconclusionsarethoseoftheauthors
andnooYcialendorsementbyManitobaHealth,theManitobaCentreforHealthPolicyor
otherdataprovidersisintendedorshouldbeinferred.
Appendix 1
Benzodiazepinesandrelatedmedications
Alprazolam, bramazepam, chlordiazepoxide, clobazam, clonazepam, diazepam,
ﬂurazepam,lorazepam,oxazepam,temazepam,triazolam,zaleplonandzopiclone.
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